Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:50873 |
Name | follicular lymphoma |
Definition | A B-cell lymphoma that is characterized as an indolent non-Hodgkin's lymphoma and has_material_basis_in follicle center B-cells (centrocytes and centroblasts). |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma follicular lymphoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
Unknown unknown | Abexinostat | follicular lymphoma | not applicable | detail... |
Unknown unknown | Copanlisib | follicular lymphoma | not applicable | detail... |
Unknown unknown | Ublituximab + Umbralisib | follicular lymphoma | not applicable | detail... |
Unknown unknown | Bendamustine + Bortezomib + Rituximab | follicular lymphoma | not applicable | detail... |
EZH2 positive | Tazemetostat | follicular lymphoma | predicted - sensitive | detail... |
Unknown unknown | Ocaratuzumab | follicular lymphoma | not applicable | detail... |
Unknown unknown | CPI-0610 | follicular lymphoma | not applicable | detail... |
Unknown unknown | Bendamustine + Obinutuzumab | follicular lymphoma | not applicable | detail... |
Unknown unknown | Rituximab | follicular lymphoma | not applicable | detail... |
Unknown unknown | Ibrutinib + Venetoclax | follicular lymphoma | not applicable | detail... |
Unknown unknown | Bendamustine + Veliparib | follicular lymphoma | not applicable | detail... |
Unknown unknown | Bendamustine + Rituximab + Veliparib | follicular lymphoma | not applicable | detail... |
Unknown unknown | Umbralisib | follicular lymphoma | not applicable | detail... |
Unknown unknown | Buparlisib + Ibrutinib | follicular lymphoma | not applicable | detail... |
Unknown unknown | Hu5F9-G4 + Rituximab | follicular lymphoma | not applicable | detail... |
Unknown unknown | Parsaclisib | follicular lymphoma | not applicable | detail... |
Unknown unknown | Idelalisib | follicular lymphoma | not applicable | detail... |
Unknown unknown | Lenalidomide + Rituximab | follicular lymphoma | not applicable | detail... |
Unknown unknown | APG-2575 + Ibrutinib | follicular lymphoma | not applicable | detail... |
EZH2 mutant | Tazemetostat | follicular lymphoma | sensitive | detail... |
Unknown unknown | Tazemetostat | follicular lymphoma | not applicable | detail... |
Unknown unknown | Tafasitamab-cxix | follicular lymphoma | not applicable | detail... |
Unknown unknown | ME-401 | follicular lymphoma | not applicable | detail... |
EZH2 A692V | Tazemetostat | follicular lymphoma | sensitive | detail... |
EZH2 A682G | Tazemetostat | follicular lymphoma | sensitive | detail... |
EZH2 Y646C | Tazemetostat | follicular lymphoma | sensitive | detail... |
EZH2 Y646S | Tazemetostat | follicular lymphoma | sensitive | detail... |
EZH2 Y646H | Tazemetostat | follicular lymphoma | sensitive | detail... |
EZH2 Y646F | Tazemetostat | follicular lymphoma | sensitive | detail... |
EZH2 Y646N | Tazemetostat | follicular lymphoma | sensitive | detail... |
EZH2 A687V | Tazemetostat | follicular lymphoma | sensitive | detail... |
EZH2 A677G | Tazemetostat | follicular lymphoma | sensitive | detail... |
EZH2 Y641N | Tazemetostat | follicular lymphoma | sensitive | detail... |
EZH2 Y641F | Tazemetostat | follicular lymphoma | sensitive | detail... |
EZH2 Y641H | Tazemetostat | follicular lymphoma | sensitive | detail... |
EZH2 Y641C | Tazemetostat | follicular lymphoma | sensitive | detail... |
EZH2 Y641S | Tazemetostat | follicular lymphoma | sensitive | detail... |
Unknown unknown | Mivavotinib | follicular lymphoma | not applicable | detail... |
Unknown unknown | Urelumab | follicular lymphoma | not applicable | detail... |
Unknown unknown | Rituximab + Urelumab | follicular lymphoma | not applicable | detail... |
Unknown unknown | Cerdulatinib | follicular lymphoma | not applicable | detail... |
Unknown unknown | Varlilumab | follicular lymphoma | not applicable | detail... |
Unknown unknown | Betalutin | follicular lymphoma | not applicable | detail... |
Unknown unknown | Pinatuzumab Vedotin + Rituximab | follicular lymphoma | not applicable | detail... |
Unknown unknown | Polatuzumab vedotin-piiq + Rituximab | follicular lymphoma | not applicable | detail... |
Unknown unknown | Lisocabtagene maraleucel | follicular lymphoma | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00577278 | Phase II | Ibritumomab tiuxetan Methotrexate + Sirolimus + Tacrolimus Rituximab Fludarabine + Melphalan | Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT00602693 | Phase I | Sirolimus Allopurinol + Cyclophosphamide + Fludarabine | T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer | Completed | USA | 0 |
NCT00671112 | Phase I | Bortezomib + Everolimus | Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma | Terminated | USA | 0 |
NCT01028716 | Phase II | Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Recruiting | USA | 0 |
NCT01193842 | Phase Ib/II | Vorinostat Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine Sulfate | Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas | Active, not recruiting | USA | 0 |
NCT01216683 | Phase II | Bendamustine + Rituximab Bortezomib Lenalidomide | Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma | Active, not recruiting | USA | 0 |
NCT01286272 | Phase II | Bendamustine + Ofatumumab Bendamustine + Bortezomib + Ofatumumab | Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT01307267 | Phase I | Rituximab + Utomilumab Utomilumab | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | Completed | USA | 4 |
NCT01691898 | Phase Ib/II | Obinutuzumab + Pinatuzumab Vedotin + Rituximab Pinatuzumab Vedotin + Polatuzumab vedotin-piiq + Rituximab Obinutuzumab + Polatuzumab vedotin-piiq | A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (ROMULUS) | Completed | USA | CAN | 4 |
NCT01719250 | Phase I | Buparlisib | Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT01732913 | Phase III | Idelalisib Rituximab | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | Terminated | USA | 18 |
NCT01732926 | Phase III | Idelalisib Bendamustine + Rituximab | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | Terminated | USA | CAN | 13 |
NCT01796171 | Phase Ib/II | Lilotomab Betalutin Rituximab | A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01) | Recruiting | USA | CAN | 22 |
NCT01804686 | Phase III | Ibrutinib | A Long-term Extension Study of PCI-32765 (Ibrutinib) | Enrolling by invitation | USA | CAN | 26 |
NCT01811368 | Phase II | anti-thymocyte globulin + Ibritumomab tiuxetan + Rituximab Cyclosporine + Mycophenolate mofetil | Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT01897012 | Phase I | Romidepsin Alisertib | Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas | Completed | USA | 0 |
NCT01953692 | Phase I | Pembrolizumab | A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013) | Completed | 0 | |
NCT01955499 | Phase I | Ibrutinib + Lenalidomide | Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Active, not recruiting | USA | CAN | 0 |
NCT01974440 | Phase III | Ibrutinib Bendamustine + Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate | A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma | Active, not recruiting | USA | 18 |
NCT01976585 | Phase Ib/II | CDX-301 + Poly ICLC | In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy | Recruiting | USA | 0 |
NCT01994382 | Phase I | Cerdulatinib | Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT02038946 | Phase II | Nivolumab | Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140) | Active, not recruiting | USA | CAN | 10 |
NCT02049541 | Phase I | Buparlisib + Rituximab | Study of BKM120; Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT02082977 | Phase I | GSK126 | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell and Transformed Follicular Lymphoma | Terminated | USA | 2 |
NCT02106091 | Phase I | AFM11 | Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL | Terminated | USA | 3 |
NCT02187861 | Phase II | Bendamustine + Rituximab Bendamustine + Rituximab + Venetoclax Rituximab + Venetoclax | A Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or GDC-0199 Plus Rituximab in Patients With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma | Completed | USA | CAN | 6 |
NCT02194751 | Phase II | Oncoquest-L vaccine | Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma | Not yet recruiting | USA | 0 |
NCT02208037 | Phase II | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) | Completed | USA | 0 | |
NCT02220842 | Phase I | Atezolizumab + Obinutuzumab | A Safety and Pharmacology Study of MPDL3280A Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma | Completed | USA | 4 |
NCT02254772 | Phase Ib/II | Ipilimumab + SD-101 | TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma | Completed | USA | 0 |
NCT02257567 | Phase Ib/II | Bendamustine + Rituximab Polatuzumab vedotin-piiq Obinutuzumab | A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma | Active, not recruiting | USA | CAN | 11 |
NCT02266147 | Phase Ib/II | SD-101 | Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma | Terminated | USA | 0 |
NCT02282358 | Phase Ib/II | Mocetinostat | Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | Active, not recruiting | USA | 0 |
NCT02320292 | Phase III | Rituximab Ibritumomab tiuxetan + Rituximab | Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma | Suspended | USA | 0 |
NCT02339922 | Phase II | Ixazomib + Rituximab | Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT02343536 | Phase I | Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Azacitidine | A Phase 1, Open-label,Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma | Completed | USA | 0 |
NCT02348216 | Phase Ib/II | KTE-C19 | A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) | Active, not recruiting | USA | CAN | 4 |
NCT02367040 | Phase III | Rituximab Copanlisib | Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) | Active, not recruiting | USA | 36 |
NCT02369016 | Phase III | Copanlisib | Phase III Copanlisib in Rituximab-refractory iNHL | Active, not recruiting | 12 | |
NCT02376699 | Phase I | Pembrolizumab + SEA-CD40 SEA-CD40 | Safety Study of SEA-CD40 in Cancer Patients | Recruiting | USA | 0 |
NCT02381080 | Phase I | Erythromycin + Ibrutinib + Voriconazole | Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy | Completed | CAN | 2 |
NCT02384954 | Phase Ib/II | ALT-803 + Rituximab | ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab | Terminated | USA | 0 |
NCT02401048 | Phase Ib/II | Durvalumab + Ibrutinib | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas | Completed | USA | 0 |
NCT02440685 | Phase Ib/II | ASN002 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | Terminated | USA | 1 |
NCT02446457 | Phase II | Pembrolizumab + Rituximab | Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma | Recruiting | USA | 0 |
NCT02454270 | Phase II | JNJ-64052781 | A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies | Terminated | USA | 4 |
NCT02457598 | Phase I | Entospletinib + Tirabrutinib Tirabrutinib Idelalisib + Obinutuzumab + Tirabrutinib Entospletinib + Obinutuzumab + Tirabrutinib Idelalisib + Tirabrutinib | Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies | Active, not recruiting | USA | 2 |
NCT02471911 | Phase I | Dexamethasone Carboplatin + Etoposide + Ifosfamide + Rituximab Selinexor | KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT02501473 | Phase Ib/II | GLA-SE + Pembrolizumab | Study of Intratumoral G100 Therapy in Patients With Or Without Pembrolizumab With Follicular Non-Hodgkin's Lymphoma | Terminated | 0 | |
NCT02532192 | Phase I | Rituximab Cisplatin Dexamethasone Cytarabine Fluconazole Belinostat | A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Withdrawn | 0 | |
NCT02532257 | Phase II | Ibrutinib + Lenalidomide + Rituximab | Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma | Active, not recruiting | USA | 0 |
NCT02536300 | Phase III | Idelalisib | Dose Optimization Study of Idelalisib in Follicular Lymphoma | Recruiting | USA | CAN | 9 |
NCT02564744 | Phase II | Naratuximab Emtansine + Rituximab | Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL | Active, not recruiting | USA | 8 |
NCT02576275 | Phase III | Bendamustine + Rituximab Duvelisib | A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | Withdrawn | USA | 0 |
NCT02596971 | Phase Ib/II | Atezolizumab + Bendamustine + Obinutuzumab Atezolizumab + Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine Sulfate Atezolizumab + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) | Completed | USA | 2 |
NCT02600897 | Phase Ib/II | Lenalidomide + Rituximab Lenalidomide + Obinutuzumab Lenalidomide + Polatuzumab vedotin-piiq + Rituximab Lenalidomide + Obinutuzumab + Polatuzumab vedotin-piiq | A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Active, not recruiting | USA | 2 |
NCT02603445 | Phase I | BCL201 + Idelalisib | Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL | Completed | USA | 3 |
NCT02605694 | Phase II | Duvelisib + Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO) | Withdrawn | USA | 0 |
NCT02611323 | Phase Ib/II | Polatuzumab vedotin-piiq + Rituximab + Venetoclax Obinutuzumab + Polatuzumab vedotin-piiq + Venetoclax | A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) | Active, not recruiting | USA | 2 |
NCT02624986 | Phase Ib/II | Idasanutlin + Obinutuzumab | A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) | Terminated | USA | 4 |
NCT02626455 | Phase III | Vincristine Sulfate Prednisone Aldoxorubicin + Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Copanlisib Bendamustine + Rituximab Rituximab | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) | Active, not recruiting | USA | CAN | 33 |
NCT02631044 | Phase I | Lisocabtagene maraleucel | Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | Recruiting | USA | 0 |
NCT02631577 | Phase I | Atezolizumab + Lenalidomide + Obinutuzumab | A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma | Completed | USA | 1 |
NCT02650999 | Phase Ib/II | Pembrolizumab | Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas | Active, not recruiting | USA | 0 |
NCT02700022 | Phase I | Alisertib Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine Sulfate | A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas | Terminated | USA | 0 |
NCT02722668 | Phase II | Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | Recruiting | USA | 0 |
NCT02729896 | Phase Ib/II | Obinutuzumab + Polatuzumab vedotin-piiq + Rituximab Atezolizumab + Obinutuzumab + Polatuzumab vedotin-piiq | A Study of Obinutuzumab, Polatuzumab Vedotin, and Atezolizumab in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) | Completed | USA | 2 |
NCT02743546 | Phase I | Ibrutinib + JNJ-64052781 | Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma | Withdrawn | 0 | |
NCT02747043 | Phase III | ABP 798 Rituximab | Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab (JASMINE) | Completed | USA | CAN | 18 |
NCT02756247 | Phase I | Buparlisib + Ibrutinib | A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma | Active, not recruiting | USA | 0 |
NCT02776813 | Phase I | ACTR087 + Rituximab | Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma | Completed | USA | 0 |
NCT02797470 | Phase Ib/II | Carmustine + CCR5 shRNA/TRIM5a/TAR decoy-transduced CD34+ HPCs + Cytarabine + Etoposide + Melphalan | Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant | Recruiting | USA | 0 |
NCT02869633 | Phase II | Ibrutinib | Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant | Active, not recruiting | USA | 0 |
NCT02900716 | Phase I | DTRMWXHS-12 + Everolimus + Pomalidomide DTRMWXHS-12 DTRMWXHS-12 + Everolimus | Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas | Completed | USA | 0 |
NCT02914938 | Phase I | ME-401 ME-401 + Rituximab | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | Recruiting | USA | 1 |
NCT02927964 | Phase Ib/II | Ibrutinib + Radiotherapy + SD-101 | TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma | Recruiting | USA | 0 |
NCT02931110 | Phase I | CBL0137 | Study of IV CBL0137 in Previously Treated Hematological Subjects | Terminated | USA | 0 |
NCT02947347 | Phase III | Ibrutinib Ibrutinib + Rituximab | Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma | Recruiting | USA | CAN | 18 |
NCT02950220 | Phase I | Ibrutinib + Pembrolizumab | Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT02953509 | Phase Ib/II | Hu5F9-G4 + Rituximab | Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | Recruiting | USA | 1 |
NCT02956382 | Phase Ib/II | Ibrutinib + Venetoclax | Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma | Recruiting | USA | 0 |
NCT02966730 | Phase I | Ibrutinib | Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy | Terminated | USA | 0 |
NCT02992522 | Phase I | Lenalidomide + Obinutuzumab + Venetoclax | Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT03010358 | Phase Ib/II | Entospletinib + Obinutuzumab | Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03015896 | Phase Ib/II | Lenalidomide + Nivolumab | Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT03019640 | Phase II | Carmustine + Cytarabine + Etoposide + Filgrastim + Lenalidomide + Melphalan + Rituximab | Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma | Recruiting | USA | 0 |
NCT03039114 | Phase I | Bendamustine + Obinutuzumab + Parsaclisib | Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) | Active, not recruiting | USA | 5 |
NCT03085173 | Phase I | EGFRt/19-28z/4-1BBL CAR T cells | A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies | Recruiting | USA | 0 |
NCT03105336 | Phase II | KTE-C19 | A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5) | Recruiting | USA | 1 |
NCT03113422 | Phase II | Obinutuzumab Obinutuzumab + Venetoclax Bendamustine + Obinutuzumab + Venetoclax | Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy (PrE0403) | Active, not recruiting | USA | 0 |
NCT03121677 | Phase I | Nivolumab + Poly ICLC + Rituximab | Personalized Synthetic Long Peptide Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma | Recruiting | USA | 0 |
NCT03126019 | Phase II | Parsaclisib Idelalisib | An Open-Label, Randomized Study Comparing INCB050465 to Idelalisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203) | Active, not recruiting | USA | CAN | 11 |
NCT03133221 | Phase II | Idelalisib | 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation | Recruiting | USA | 0 |
NCT03135262 | Phase Ib/II | Idasanutlin + Rituximab + Venetoclax Idasanutlin + Obinutuzumab + Venetoclax Idasanutlin + Obinutuzumab + Rituximab + Venetoclax | A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL) | Terminated | USA | 4 |
NCT03147885 | Phase Ib/II | Selinexor | Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma | Unknown status | USA | 0 |
NCT03150329 | Phase I | Pembrolizumab + Vorinostat | Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT03153462 | Expanded access | Cyclophosphamide + Fludarabine + KTE-C19 | Axicabtagene Ciloleucel Expanded Access Study | Available | USA | 0 |
NCT03156114 | Phase I | BI 754091 BI 754111 | This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. | Active, not recruiting | USA | CAN | 3 |
NCT03178201 | Phase II | Umbralisib | TGR1202 in Relapsed and Refractory Follicular Lymphoma | Terminated | USA | 0 |
NCT03179930 | Phase II | Entinostat + Pembrolizumab | Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas | Recruiting | USA | 0 |
NCT03189836 | Phase I | ACTR707 + Rituximab | Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT03198026 | Phase II | Ibrutinib + Obinutuzumab | Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas | Recruiting | USA | 0 |
NCT03269669 | Phase II | Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine Sulfate Lenalidomide + Obinutuzumab Obinutuzumab + Umbralisib Prednisone | Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma | Recruiting | USA | 0 |
NCT03277729 | Phase Ib/II | CD20 CAR T-cells + Cyclophosphamide + Fludarabine | A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | Recruiting | USA | 0 |
NCT03297424 | Phase Ib/II | PLX2853 | A Study of PLX2853 in Advanced Malignancies. | Recruiting | USA | 0 |
NCT03321643 | Phase I | Atezolizumab + Gemcitabine + Oxaliplatin + Rituximab Atezolizumab + Rituximab | Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT03332017 | Phase II | Obinutuzumab + Zanubrutinib Obinutuzumab | A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma | Recruiting | USA | CAN | 15 |
NCT03357627 | Phase I | Mivavotinib + Venetoclax | A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma | Active, not recruiting | USA | CAN | 1 |
NCT03361852 | Phase I | NeoVax + Rituximab | A Pilot Study of a Personalized Neoantigen Cancer Vaccine Following Front-Line Rituximab in Follicular Lymphoma | Not yet recruiting | USA | 0 |
NCT03379493 | Phase I | Study of ET190L1-ARTEMIS T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma | Terminated | USA | 0 | |
NCT03401853 | Phase II | Pembrolizumab + Rituximab | Rituximab and Pembrolizumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma | Recruiting | USA | 0 |
NCT03422679 | Phase Ib/II | CB-103 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | Recruiting | USA | 3 |
NCT03424122 | Phase I | Ibrutinib + Parsaclisib Bendamustine + Parsaclisib + Rituximab Parsaclisib + Rituximab | INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) | Active, not recruiting | USA | 2 |
NCT03424603 | Phase I | STRO-001 | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | Recruiting | USA | 0 |
NCT03460977 | Phase I | PF-06821497 | PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma | Recruiting | USA | 3 |
NCT03465891 | Phase II | Atezolizumab | Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma | Terminated | USA | 0 |
NCT03479268 | Phase I | Ibrutinib + MLN4924 | Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT03483103 | Phase II | Lisocabtagene maraleucel | Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) | Active, not recruiting | USA | 0 |
NCT03498612 | Phase II | Pembrolizumab | Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases | Recruiting | USA | 0 |
NCT03547115 | Phase I | Voruciclib | A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies | Recruiting | USA | 0 |
NCT03568461 | Phase II | Tisagenlecleucel | Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma (ELARA) | Active, not recruiting | USA | 11 |
NCT03571568 | Phase Ib/II | BI-1206 + Rituximab | A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | 3 |
NCT03571828 | Phase I | AMG562 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma | Active, not recruiting | USA | CAN | 1 |
NCT03579927 | Phase Ib/II | Filgrastim iC9-CAR.19-IL15-Transduced CB-NK Carmustine + Cytarabine + Etoposide + Melphalan + Rituximab | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma | Withdrawn | USA | 0 |
NCT03585725 | Phase I | Ribavirin | A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma | Recruiting | USA | 0 |
NCT03600441 | Phase II | Abexinostat | Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER) | Active, not recruiting | USA | 2 |
NCT03610724 | Phase II | Tisagenlecleucel | Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients (BIANCA) | Recruiting | USA | CAN | 12 |
NCT03636503 | Phase I | Avelumab + Rituximab + Utomilumab Avelumab + PF-04518600 + Rituximab PF-04518600 + Rituximab + Utomilumab | RITUXIMAB + IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA | Recruiting | USA | 0 |
NCT03671018 | Phase I | Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Bendamustine + Polatuzumab vedotin-piiq + Rituximab Bendamustine + Obinutuzumab BTCT4465A + Polatuzumab vedotin-piiq BTCT4465A Obinutuzumab Tocilizumab | A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | CAN | 0 |
NCT03682796 | Phase I | TRPH-222 | Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma | Recruiting | USA | CAN | 0 |
NCT03685344 | Phase I | Durvalumab + Loncastuximab tesirine | Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma | Terminated | USA | 1 |
NCT03696784 | Phase I | Rimiducid Bendamustine + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK | Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | Recruiting | USA | 0 |
NCT03711578 | Phase II | Tenalisib | Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K delta/gamma Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) | Completed | USA | 1 |
NCT03740529 | Phase Ib/II | Cyclophosphamide + Doxorubicin + LOXO-305 + Prednisone + Rituximab + Vincristine Sulfate LOXO-305 + Rituximab + Venetoclax LOXO-305 + Venetoclax LOXO-305 | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | Recruiting | USA | 7 |
NCT03744676 | Phase II | Lisocabtagene maraleucel | A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Ldymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) | Recruiting | USA | 0 |
NCT03758989 | Phase II | Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma | Recruiting | USA | 0 |
NCT03768505 | Phase II | ME-401 | Study of ME-401 in Subjects With Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies | Recruiting | USA | 13 |
NCT03779113 | Phase Ib/II | HMPL-523 | An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma | Recruiting | USA | 3 |
NCT03786926 | Phase Ib/II | HMPL-689 | Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas | Recruiting | USA | 3 |
NCT03789240 | Phase II | Copanlisib + Rituximab | Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma | Active, not recruiting | USA | 0 |
NCT03828448 | Phase II | Ublituximab + Umbralisib | Study to Assess Umbralisib Plus Ublituximab in Patients With Treatment Naive Follicular Lymphoma | Recruiting | USA | 0 |
NCT03833180 | Phase I | VLS-101 | A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies | Recruiting | USA | 0 |
NCT03884998 | Phase I | Copanlisib + Nivolumab | Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma | Recruiting | USA | 0 |
NCT03888105 | Phase II | Odronextamab | Assess the Anti-Tumor Activity and Safety of REGN1979 in Patients With Relapsed or Refractory Follicular Lymphoma | Active, not recruiting | USA | CAN | 10 |
NCT03892044 | Phase I | Duvelisib + Nivolumab | Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma | Recruiting | USA | 0 |
NCT03919175 | Phase II | Rituximab + Umbralisib | Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma | Recruiting | USA | 0 |
NCT03920631 | Phase I | Nivolumab | Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ) | Recruiting | USA | 0 |
NCT03939026 | Phase I | UCART19 ALLO-647 + Cyclophosphamide + Fludarabine | Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma (ALPHA) | Recruiting | USA | 0 |
NCT03976102 | Phase III | Rituximab DRL_RI | Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera in LTB Follicular Lymphoma (FLINTER) (FLINTER) | Recruiting | USA | 0 |
NCT03980171 | Phase Ib/II | Lenalidomide + Obinutuzumab + Venetoclax | Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma (LEVERAGE) | Recruiting | USA | 1 |
NCT04007029 | Phase I | Tocilizumab Anti-CD19-CD20 CAR T cells + Cyclophosphamide + Fludarabine | Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia | Recruiting | USA | 0 |
NCT04014205 | Phase I | Orelabrutinib | A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies | Recruiting | USA | 0 |
NCT04038359 | Phase II | Duvelisib | A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma. (TEMPO) | Recruiting | USA | 7 |
NCT04074330 | Phase Ib/II | Rituximab + TAK-981 | A Study of TAK-981 in Combination With Rituximab in Participants With Relapsed/Refractory (r/r) CD20-positive (CD20+) Non-Hodgkin Lymphoma (NHL) | Recruiting | USA | CAN | 0 |
NCT04082936 | Phase I | IGM-2323 | A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma | Recruiting | USA | 2 |
NCT04136275 | Phase I | Anti-CD37 CAR T cells | CAR-37 T Cells In Hematologic Malignancies | Recruiting | USA | 0 |
NCT04156828 | Phase I | Carboplatin + Copanlisib + Dexamethasone + Gemcitabine + Pegfilgrastim + Rituximab | Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma | Recruiting | USA | 0 |
NCT04205409 | Phase II | Nivolumab | Nivolumab for the Treatment of Relapsed or Refractory Hematologic Malignancies | Recruiting | USA | 0 |
NCT04223765 | Phase I | Bendamustine + CAR.k.28 cells + Fludarabine CAR.k.28 cells + Cyclophosphamide + Fludarabine | Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04224493 | Phase III | Lenalidomide + Rituximab + Tazemetostat Lenalidomide + Rituximab | Study in Subjects With Relapsed/Refractory Follicular Lymphoma | Recruiting | USA | 0 |
NCT04231747 | Phase I | CC-97540 | A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04245839 | Phase II | Lisocabtagene maraleucel Cyclophosphamide + Fludarabine | A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL) | Recruiting | USA | CAN | 8 |
NCT04246086 | Phase I | Tocilizumab Obinutuzumab Lenalidomide + Obinutuzumab + RO7082859 Lenalidomide + RO7082859 BTCT4465A + Lenalidomide | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide, Glofitamab + Lenalidomide, and Glofitamab + Lenalidomide + Obinutuzumab in Participants With Relapsed or Refractory Follicular Lymphoma | Recruiting | USA | 3 |
NCT04283097 | Phase I | KPG-818 | Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects | Recruiting | USA | 0 |
NCT04390737 | Phase I | HH2853 | A Phase I Study to Evaluate the Safety and Clinical Activity of HH2853. | Recruiting | USA | 1 |
NCT04404088 | Phase II | Acalabrutinib + Lenalidomide + Rituximab | Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma | Recruiting | USA | 0 |
NCT04419909 | Phase I | huCART19 | Retreatment With CTL019/CTL119 | Not yet recruiting | USA | 0 |
NCT04431635 | Phase I | Copanlisib + Nivolumab + Rituximab | Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma | Recruiting | USA | 0 |
NCT04447716 | Phase I | Lenalidomide + Rituximab Hyaluronidase + Venetoclax Lenalidomide + Rituximab + Venetoclax | An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment | Recruiting | USA | 0 |
NCT04450173 | Phase II | Ibrutinib + Obinutuzumab + Venetoclax | Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma | Not yet recruiting | USA | 0 |
NCT04464798 | Phase I | Iberdomide Iberdomide + Obinutuzumab Iberdomide + Rituximab | A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas | Not yet recruiting | USA | 3 |
NCT04508647 | Phase II | Ublituximab Ublituximab + Umbralisib | Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma | Recruiting | USA | 0 |
NCT04590820 | Phase II | Rituximab + Tazemetostat | Oral Tazemetostat in Combination With Rituximab in R/R FL | Not yet recruiting | USA | 0 |
NCT04599634 | Phase I | Hu5F9-G4 + Obinutuzumab + Venetoclax | Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies | Not yet recruiting | USA | 0 |
NCT04635683 | Phase I | Lenalidomide + Ublituximab + Umbralisib | Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | Not yet recruiting | USA | 0 |
NCT04659044 | Phase II | Polatuzumab vedotin-piiq + Rituximab + Rituximab Hyaluronidase + Venetoclax Rituximab Hyaluronidase + Venetoclax | Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | Not yet recruiting | USA | 0 |
NCT04722601 | Phase Ib/II | Azacitidine + Venetoclax Azacitidine + Obinutuzumab + Venetoclax Obinutuzumab | A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma | Not yet recruiting | USA | 0 |
NCT04750941 | Phase II | Copanlisib | Study of Copanlisib and Ketogenic Diet | Recruiting | USA | 0 |